Chronic obstructive pulmonary disease, a term often synonymous with long-term smokers, has a far more extensive reach than initially meets the eye. The disease disproportionately affects women and is exacerbated by environmental factors such as air pollution, which is a pressing concern in Philadelphia where the city's air quality ranks below the national average.
According to federal data, COPD affects an estimated 11 million adults nationwide - approximately 4% of all U.S. adults - claiming around 142,000 lives each year. While smoking is responsible for up to three-quarters of these cases, exposure to long-term air pollution and other irritants plays a significant role in the development of the disease.
Dr. Gerard Criner, director of the Temple Health Lung Center, emphasizes that COPD is not solely a smoker's disease but rather a condition influenced by various factors including environmental pollutants and occupational health hazards. The temple expert notes that non-smokers are also at risk for developing COPD if exposed to poor air quality or other hazardous conditions.
Symptoms of COPD can be subtle yet debilitating, including frequent coughing, wheezing, shortness of breath, particularly during exercise, and chest tightness. Despite these warning signs, many cases remain undiagnosed, with women being disproportionately affected by the disease.
Research reveals that more women than men are diagnosed with COPD, and women often experience more severe symptoms. The Temple Lung Center's Dr. Jamie Garfield explains that this disparity may be attributed to women having smaller lungs and airways, making them more susceptible to damage from pollutants.
The temple lung center has established itself as a leading institution in COPD research, treatment, and innovation under the direction of Dr. Gerard Criner. They offer comprehensive care plans tailored to individual needs and provide access to clinical trials that test new therapies. In fact, Temple's experts have contributed to global standards for COPD management.
However, Philadelphia's air quality adds a critical layer to the urgency around COPD awareness. The American Lung Association's 2025 "State of the Air" report gave Philadelphia County an F grade for particle pollution, ranking it among the worst in the country and third worst in the Mid-Atlantic region.
Recent breakthroughs at Temple include participation in the BREATHE-3 clinical trial, which aims to relieve trapped air in the lungs with a new bronchoscopic device. With research like this, there is growing hope for COPD patients who currently have limited treatment options.
Ultimately, the future of COPD care lies not just in managing symptoms but in creating treatments that allow patients to live fuller lives. Dr. Gerard Criner emphasizes that every breakthrough achieved at Temple brings us closer to this goal.
According to federal data, COPD affects an estimated 11 million adults nationwide - approximately 4% of all U.S. adults - claiming around 142,000 lives each year. While smoking is responsible for up to three-quarters of these cases, exposure to long-term air pollution and other irritants plays a significant role in the development of the disease.
Dr. Gerard Criner, director of the Temple Health Lung Center, emphasizes that COPD is not solely a smoker's disease but rather a condition influenced by various factors including environmental pollutants and occupational health hazards. The temple expert notes that non-smokers are also at risk for developing COPD if exposed to poor air quality or other hazardous conditions.
Symptoms of COPD can be subtle yet debilitating, including frequent coughing, wheezing, shortness of breath, particularly during exercise, and chest tightness. Despite these warning signs, many cases remain undiagnosed, with women being disproportionately affected by the disease.
Research reveals that more women than men are diagnosed with COPD, and women often experience more severe symptoms. The Temple Lung Center's Dr. Jamie Garfield explains that this disparity may be attributed to women having smaller lungs and airways, making them more susceptible to damage from pollutants.
The temple lung center has established itself as a leading institution in COPD research, treatment, and innovation under the direction of Dr. Gerard Criner. They offer comprehensive care plans tailored to individual needs and provide access to clinical trials that test new therapies. In fact, Temple's experts have contributed to global standards for COPD management.
However, Philadelphia's air quality adds a critical layer to the urgency around COPD awareness. The American Lung Association's 2025 "State of the Air" report gave Philadelphia County an F grade for particle pollution, ranking it among the worst in the country and third worst in the Mid-Atlantic region.
Recent breakthroughs at Temple include participation in the BREATHE-3 clinical trial, which aims to relieve trapped air in the lungs with a new bronchoscopic device. With research like this, there is growing hope for COPD patients who currently have limited treatment options.
Ultimately, the future of COPD care lies not just in managing symptoms but in creating treatments that allow patients to live fuller lives. Dr. Gerard Criner emphasizes that every breakthrough achieved at Temple brings us closer to this goal.